Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat

Diabetes, Obesity and Metabolism

Volumn 12, Issue 2, 2010, Pages 139-147

  Hassanali, Z ^a   Ametaj, B N ^a   Field, C J ^a   Proctor, S D ^a   Vine, D F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Inflammation; Metabolic syndrome; N 3 PUFA; Postprandial lipaemia

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B48; CHYLOMICRON; HAPTOGLOBIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; FOOD INTAKE; HYPERLIPIDEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 73449142133     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01130.x     Document Type: Article

References (60)

1. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106:83-97.
2. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998, 141(Suppl. 1):S63-S69. (Review).
3. Cabezas MC, Erkelens DW. Triglycerides and atherosclerosis: to feast or fast. Neth J Med 2000, 56:110-118. (Review).
4. Mamo JC, Yu KC, Elsegood CL. Is atherosclerosis exclusively a postprandial phenomenon? Clin Exp Pharmacol Physiol 1997, 24:288-293. (Review).
5. Weintraub MS, Grosskopf I, Rassin T. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. Br Med J 1996, 312:935-939.
6. Cabezas MC, de Bruin TW, Westerveld HE, Meijer E, Erkelens DW. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Intern Med 1998, 244:299-307.
7. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002, 13:461-470.
8. Proctor SD, Vine DF, Mamo JC. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 2004, 24:2162-2167.
9. Proctor SD, Mamo JC. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2003, 23:1595-1600.
10. Couillard C, Bergeron N, Prud'homme D. Postprandial triglyceride response in visceral obesity in men. Diabetes 1998, 47:953-960.
11. Blackburn P, Lamarche B, Couillard C. Postprandial hyperlipidemia: another correlate of the " hypertriglyceridemic waist" phenotype in men. Atherosclerosis 2003, 171:327-336.
12. De Man FH, Cabezas MC, Van Barlingen HH, Erkelens DW, de Bruin TW. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996, 26:89-108.
13. Taskinen MR. Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001, 109(Suppl. 2):S180-S188. (Review).
14. Alipour A, Elte JW, van Zaanen HC, Rietveld AP, Cabezas MC. Postprandial inflammation and endothelial dysfunction. Biochem Soc Trans 2007, 35:466-469. (Review).
15. van Oostrom AJ, van Wijk J, Cabezas MC. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 2004, 64(Suppl. 2):19-41. (Review).
16. Van Oostrom AJ, Sijmonsma TP, Rabelink TJ, Van Asbeck BS, Cabezas MC. Postprandial leukocyte increase in healthy subjects. Metabolism 2003, 52:199-202.
17. Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans: a review. J Nutr Biochem 2006, 17:1-13. (Review).
18. Roche HM, Gibney MJ. Long-chain n-3 polyunsaturated fatty acids and triacylglycerol metabolism in the postprandial state. Lipids 1999, 34(Suppl):S259-S265. (Review).
19. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005, 105:428-440. (Review).
20. Harris WS, Connor WE, Illingworth DR, Rothrock DW, Foster DM. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 1990, 31:1549-1558.
21. Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984, 74:82-89.
22. Wong SH, Fisher EA, Marsh JB. Effects of eicosapentaenoic and docosahexaenoic acids on apoprotein B mRNA and secretion of very low density lipoprotein in HepG2 cells. Arteriosclerosis 1989, 9:836-841.
23. Dolphin PJ, Amy RM, Koeslag DG, Limoges BF, Russell JC. Reduction of hyperlipidemia in the LA/N-corpulent rat by dietary fish oil containing n-3 fatty acids. Biochim Biophys Acta 1988, 962:317-329.
24. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65:1645S-1654S. (Review).
25. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007, 190:282-290.
26. Mangat R, Su J, Scott PG, Russell JC, Vine DF, Proctor SD. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans 2007, 35:477-481. (Review).
27. Russell JC, Koeslag DG, Amy RM, Dolphin PJ. Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats. Arteriosclerosis 1989, 9:869-876.
28. Smith D, Proctor SD, Mamo JC. A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann Clin Biochem 1997, 34:185-189.
29. Li JJ, Huang CJ, Xie D. Anti-obesity effects of conjugated linoleic acid, docosahexaenoic acid, and eicosapentaenoic acid. Mol Nutr Food Res 2008, 52:631-645.
30. Dziedzic B, Szemraj J, Bartkoiak J, Walczewska A. Various dietary fats differentially change the gene expression of neuropeptides involved in body weight regulation in rats. J Neuroendocrinol 2007, 19:364-373.
31. Kesavulu MM, Kameswararao B, Apparao Ch, Kumar EG, Harinarayan CV. Effect of omega-3 fatty acids on lipid peroxidation and anti-oxidant enzyme status in type 2 diabetic patients. Diabetes Metab 2002, 28:20-26.
32. Clarke SD, Jump DB. Dietary polyunsaturated fatty acid regulation of gene transcription. Annu Rev Nutr 1994, 14:83-98. (Review).
33. Jump DB, Thelen A, Mater M. Dietary polyunsaturated fatty acids and hepatic gene expression. Lipids 1999, 34(Suppl.):S209-S212. (Review).
34. Xu J, Teran-Garcia M, Park JH, Nakamura MT, Clarke SD. PUFA suppress hepatic SREBP-1 expression by accelerating transcript decay. J Biol Chem 2001, 276:9800-9807.
35. Halvorsen B, Rustan AC, Madsen L. Effects of long-chain monounsaturated and n-3 fatty acids on fatty acid oxidation and lipid composition. Ann Nutr Metab 2001, 45:30-37.
36. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000, 23:1407-1415. (Review).
37. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998, 21:494-500.
38. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002, 76:1007-1015.
39. MacLean CH, Mojica WA, Morton SC. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ) 2004, (89):1-4.
40. Satoh N, Shimatsu A, Kotani K. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007, 30:144-146.
41. Elam MB, Wilcox HG, Cagen LM. Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. J Lipid Res 2001, 42:2039-2048.
42. Deng X, Elam MB, Wilcox HG. Dietary olive oil and menhaden oil mitigate induction of lipogenesis in hyperinsulinemic corpulent JCR:LA-cp rats: microarray analysis of lipid-related gene expression. Endocrinology 2004, 145:5847-5861.
43. Foufelle F, Girard J, Ferré P. Regulation of lipogenic enzyme expression by glucose in liver and adipose tissue: a review of the potential cellular and molecular mechanisms. Adv Enzyme Regul 1996, 36:199-226. (Review).
44. Girard J, Perdereau D, Foufelle F, Prip-Buus C, Ferré P. Regulation of lipogenic enzyme gene expression by nutrients and hormones. FASEB J 1994, 8:36-42. (Review).
45. Lombardo YB, Hein G, Chicco A. Metabolic syndrome: effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity. Lipids 2007, 42:427-437.
46. Drevon CA. Fatty acids and expression of adipokines. Biochim Biophys Acta 2005, 1740:287-292.
47. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 2008, 57:1824-1833.
48. Levy E, Spahis S, Ziv E. Overproduction of intes-tinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia 2006, 49:1937-1945.
49. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006, 17:387-393.
50. Ikeda I, Kumamaru J, Nakatani N, Sakono M, Murota I, Imaizumi K. Reduced hepatic triglyceride secretion in rats fed docosahexaenoic acid-rich fish oil suppresses postprandial hypertriglyceridemia. J Nutr 2001, 131:1159-1164.
51. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003, 44:455-463.
52. Ranheim T, Gedde-Dahl A, Rustan AC, Drevon CA. Influence of eicosapentaenoic acid (20:5, n-3) on secretion of lipoproteins in Caco-2 cells. J Lipid Res 1992, 33:1281-1293.
53. Burdge GC, Calder PC. Plasma cytokine response during the postprandial period: a potential causal process in vascular disease? Br J Nutr 2005, 93:3-9. (Review).
54. Madsen T, Christensen JH, Schmidt EB. C-reactive protein and n-3 fatty acids in patients with a previous myocardial infarction: a placebo-controlled randomized study. Eur J Nutr 2007, 46:428-430.
55. Giffen PS, Turton J, Andrews CM. Markers of experimental acute inflammation in the Wistar Han rat particular reference to haptoglobin and C-reactive protein. Arch Toxicol 2003, 77:392-402.
56. Vreugdenhil AC, Snoek AM, van ' Veer C, Greve JW, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001, 107:225-234.
57. Schröder NW, Heine H, Alexander C. Lipopoly-saccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol 2004, 173:2683-2691.
58. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009, 50:90-97.
59. Berstad P, Seljeflot I, Veierød MB, Hjerkinn EM, Arnesen H, Pedersen JI. Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin Sci (Lond) 2003, 105:13-20.
60. Eschen O, Christensen JH, De Caterina R, Schmidt EB. Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 2004, 14:180-185.